For research use only. Not for therapeutic Use.
Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin[1][2].
| Catalog Number | I010456 |
| CAS Number | 72420-38-3 |
| Synonyms | 5-methyl-4-oxo-5-phenylfuran-2-carboxylic acid |
| Molecular Formula | C12H10O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15) |
| InChIKey | DFDGRKNOFOJBAJ-UHFFFAOYSA-N |
| SMILES | CC1(C(=O)C=C(O1)C(=O)O)C2=CC=CC=C2 |
| Reference | [1]. M N Cayen, et al. The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. Xenobiotica. 1986 Mar;16(3):251-63. [2]. Jae-Kyu Jung, et al. Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8. |
